This clinical trial is focused on studying polycythemia vera, a condition where the body produces too many red blood cells, which can lead to complications like blood clots. The study will use a medication called hydroxyurea, also known as hydroxycarbamide, which is commonly used to manage this condition. The purpose of the study is to evaluate how patients with polycythemia vera respond to hydroxyurea, particularly looking at resistance or intolerance to the medication.
Participants in the study will begin their regular treatment with hydroxyurea, and researchers will monitor them over a period of up to 15 months. The study will use advanced techniques, including artificial intelligence, to identify patients who might be resistant to hydroxyurea before they start treatment. This will help in understanding which patients are more likely to benefit from the medication and who might need alternative treatments.
Throughout the study, researchers will observe how many patients develop resistance or intolerance to hydroxyurea within the first 6 to 9 months and over the entire 15-month period. They will also look at the reasons why some patients might need to switch to different therapies and the timing of these changes. This information will be valuable in improving treatment strategies for polycythemia vera in the future.
Germany 
